Eibsee: Keynote on Anti-amyloid Drugs, Prevention
Todd Golde subsumed summaries of new data from three research areas in his laboratory under a broader theme that is coming to the fore across the field...
1380 RESULTS
Sort By:
Todd Golde subsumed summaries of new data from three research areas in his laboratory under a broader theme that is coming to the fore across the field...
As scientists around the world enjoy their holiday family retreat, a few of them may recall a recent gathering of a different sort...
Specificity is a big issue for drug makers as side effects due to unpredicted interactions can scuttle potential pharmaceuticals...
While some neurodegenerative disease therapies focus on signature proteins, a growing number are addressing more fundamentally what sets neurons up for self-destruction...
In the spinal cord, as in life, too much of a good thing can be detrimental...
Researchers are not shy about putting new therapies through preclinical paces...
Widely seen as the molecular trigger for a cascade of changes leading to AD, Aβ lurks within the brains of many cognitively normal seniors, too...
The mSOD1 mouse, harboring a mutated human superoxide dismutase (SOD1) gene, has long held the spotlight as the model of choice for ALS...
Once thought to be a simple go-between, RNA is recently attracting much more attention as an important regulator of gene expression in its own right...
Loaded with promise and disappointment, the roller-coaster tale of Alzheimer disease vaccine development has raised hopes and dampened some...
Gumming up the brain years before a person may notice memory loss or other hints of Alzheimer disease, amyloid-β (Aβ) has fueled much of AD research...
Neprilysin, one of a handful of proteases known to degrade amyloid-β (Aβ), might seem an attractive therapeutic for Alzheimer disease...
In an effort to bring together neuroscience researchers from the East and the West, the 2008 Beijing Symposium on Aging and Neurodegeneration (BSAN) was initiated in March 2008...
While the media focuses on the next potential billion-dollar pharmaceutical treatment of AD, other investigators have been quietly cooking up alternative approaches...
Two anti-amyloid approaches—PBT2 and IVIg—came out with Phase 2 data at ICAD...